Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody

Clinical Pharmacokinetics

Volumn 51, Issue 6, 2012, Pages

  Chakraborty, Abhijit ^a   Tannenbaum, Stacey ^b   Rordorf, Christiane ^b   Lowe, Philip J ^b   Floch, David ^b   Gram, Hermann ^b   Roy, Sandip ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Canakinumab; Cryopyrin associated periodic syndromes; Interleukin 1 beta; Monoclonal antibodies; Pharmacokinetics; Pharmacology.

Indexed keywords

ALBUMIN; AMOXICILLIN; CANAKINUMAB; CEPHALOSPORIN; CORTICOSTEROID; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

AGE; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ASTHMA; BODY WEIGHT; CINCA SYNDROME; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IC 50; IMMUNOGENICITY; IN VIVO STUDY; IRON THERAPY; KIDNEY FUNCTION; LIMIT OF QUANTITATION; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENTIATION; SINGLE DRUG DOSE; STOCHASTIC MODEL;

EID: 84860426838     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11599820-000000000-00000     Document Type: Review

References (39)

1. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-25 (Pubitemid 38388233)
2. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-8 (Pubitemid 35453546)
3. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-85 (Pubitemid 39488063)
4. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86 (Pubitemid 40664091)
5. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204 (Pubitemid 29009378)
6. So A, De Smedt T, Revaz S, et al.Apilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28
7. de Kluijver J, Grunberg K, Pons D, et al. Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. Clin Exp Allergy 2003; 33: 1415-8 (Pubitemid 37289939)
8. Rupp J, Kothe H, Mueller A, et al. Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J 2003; 22: 274-9 (Pubitemid 36986997)
9. Debets R, Hegmans JP, Troost RJ, et al. Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release. Eur J Immunol 1995; 25: 1624-30
10. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-26 (Pubitemid 46588416)
11. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25
12. Bonner J, Lloyd P, Lowe P, et al. PK/PD, safety and tolerability of a human anti-IL-1B monoclonal antibody (ACZ885) in healthy subjects [abstract no. 748]. Annual Congress of the European Respiratory Society; 2006 Sep 2-6; Munich
13. Novartis. Safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 in healthy Japanese male volunteers [ClinicalTrials.gov identifier NCT00421226]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 2]
14. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R67
15. A4 week treatment study to evaluate the safety, tolerability, immunogenicity of single and multiple 150 mg subcutaneous administration of ACZ885 in psoriasis patients [EudraCT identifier 2005-004119-31] European Clinical Trial Database, EudraCT [online]. Available from URL: https://eudract. ema.europa.eu/index.html [Accessed on 2012 Apr 3]
16. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36
17. Vugmeyster Y, Tian X, Szklut P, et al. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and ascaris-challenged cynomolgus monkeys. Pharma Res 2009; 26: 306-15
18. Barnes LM, Bentley CM, Dickson AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology 2000; 32: 109-23 (Pubitemid 30166226)
19. Shulman M, Wilde CD, Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276: 269-70 (Pubitemid 9053903)
20. European Medicines Agency. Ilaris: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/doc ument-library/EPAR-Product-Information/human/001109/WC500031680. pdf [Accessed 2012 Apr 2]
21. FDA label information. Ilaris (canakinumab) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125319s000lbl. pdf [Accessed 2011 Dec 1]
22. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1-16 (Pubitemid 38900899)
23. Boon L, Brok HP, Bauer J, et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001; 167: 2942-9 (Pubitemid 32768930)
24. Beal SL, Sheiner LB, Boeckmann AJ, et al. NONMEM users guide. Ellicott City (MD): Icon Development Solutions, 2009
25. Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2006; 63: 548-61
26. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-58
27. Mould DR, Sweeney KRD. The pharmacokinetics and pharmacodynamics of monoclonal antibodies: mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10: 84-96 (Pubitemid 46438261)
28. Kopp WC, Urba WJ, Rager HC, et al. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin Cancer Res 1996; 2: 501-6 (Pubitemid 26100051)
29. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633-59
30. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws for biology. Science 1997; 276: 122-6 (Pubitemid 27161259)
31. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677-9 (Pubitemid 29291379)
32. Bouwmeester HJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesthesia 2004; 92: 208-17 (Pubitemid 38159658)
33. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4mRNAlevels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687-93 (Pubitemid 47296065)
34. Sunman JA, Hawke RL, LeCluyse EL, et al. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 2004; 32: 359-63 (Pubitemid 38263895)
35. Chaluvadi MR, Nyagode BA, Kinloch RD, et al. TLR4-dependent and-independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochem Pharmacol 2009; 77: 464-71
36. Ashino T, Arima Y, Shioda S, et al. Effect of interleukin-6 neutralization on cyp3a11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur J Pharmacol 2007; 558: 199-207 (Pubitemid 46328884)
37. Burger D, Dayer JM, Palmer G, et al. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20: 879-96 (Pubitemid 44382385)
38. Hoffman HM. Rilonacept for the treatment of cryopyrin associated periodic syndromes (CAPS). Expert Opin Biol Ther 2009; 9 (4): 519-31
39. Kuemmerle-Deschner J, Hachulla E, Cartwright R, et al.Two-year results froman open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70: 2095-102